Evaluation of the Valiant Mona LSA Thoracic Stent Graft System in Thoracic Aortic Aneurysms and Chronic Dissections
Key facts
- Who runs it
- University Hospital, Toulouse
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- Jan 2019
- Ended
- Feb 2026
- Type of study
- Interventional
- Treatments tested
- Valiant Mona LSA Thoracic Stent Graft System
- Record updated
- 26 August 2020
- Why it stopped
- Production of the medical device was stopped
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Subject is at least 18 years of age
- Subject understands and has signed an Informed Consent
- Subject must be considered a candidate for revascularization of the LSA
- Subject must be able to tolerate a surgical revascularization of the LSA
- Subject has a descending thoracic aneurysm (DTA) which will require coverage of the LSA
- Subject has a healthy, non-diseased aortic proximal seal zone of at least 10 mm from the left carotid to the LSA and at least 5 mm landing zone distal to the LSA and proximal to the start of the aneurysm/ulcer/or the proximal entry tear for dissection
- Subject has a non-diseased aortic diameter between 25 mm and 42 mm (fusiform/saccular aneurysms or penetrating ulcers) or 28 mm to 44 mm (chronic type B dissections),
- Subject has a LSA with a diameter between 8 mm and 13 mm
- Subject has sufficient landing zone within the LSA to accommodate the BSG without occlusion of any significant vessels
- Subject has patent brachial arteries, iliac or femoral arteries (without circumferential calcifications and a diameter of ≥ 10mm), or can tolerate a conduit that will allow endovascular access to the aneurysmal site with the delivery system of the appropriate sized device chosen for treatment
- Subject has a condition requiring prospective revascularization of the LSA
Who cannot take part
- Treatment with the Valiant Mona LSA Thoracic Stent Graft system would require intentional coverage of the left common carotid artery with the stent graft fabric
- Subject has coronary artery disease with unstable angina and has not received treatment
- Subject is currently participating in an investigational drug or device clinical trial that would interfere with the observations of this study
- Subject has prohibitive calcification, occlusive disease, or tortuosity of intended fixation sites
- Subject has a known allergy or intolerance to the device components
- Subject has a connective tissue disease (e.g. Marfan's syndrome, medial degeneration)
- Subject has active systemic infection and/or a mycotic aneurysm
- Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion
- Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment
- Subject is in acute renal failure or has renal insufficiency with a serum creatinine ≥ 2.0 mg/dL or is on dialysis
- Subject has an aneurysmal, tortuous, or atherosclerotic LSA, conflicting the branch graft insertion
- Subject has an aortic atheroma classified as grade IV or grade V
- Subject has significant and/or circumferential aortic mural thrombus at either the proximal or distal attachment sites that would compromise fixation and seal of the device
- Subject is a pregnant or breastfeeding female
- Subject has other medical, social, or psychological problems that, in the opinion of the investigator, will interfere with treatment and follow-up procedures
- Subject has a life expectancy of less than 1 year
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To ensure adequate seal of currently available stent grafts, a proximal 20 mm of healthy aorta is recommended. Extending the proximal landing zone into the arch by intentional covering of the left subclavian artery (LSA) without revascularization expose to serious neurologic complications. Serious risks are also known to accompany subclavian revascularization. The Valiant Mona LSA Thoracic Stent Graft System (Medtronic,Santa Rosa, Calif) consists of a main stent graft and a branch stent graft designed to maintain LSA patency. The purpose of this study is to characterize the safety and effectiveness of this device for the treatment of Aneurysms and chronic Type B dissections of the arch.
The group in the trial
- Valiant Mona LSA Thoracic Stent Graft SystemTreatment being tested
The Valiant Mona LSA Thoracic Stent Graft System is administered.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 26 August 2020